Prognostic Value of Elevated SHIP2 Expression in Laryngeal Squamous Cell Carcinoma

Archives of Medical Research

Volumn 42, Issue 7, 2011, Pages 589-595

  Zhou, Xiaojuan ^a,c   Liu, Yong ^b   Tan, Guolin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Changsha City No 1 Hospital   (China)

Author keywords

Laryngeal squamous cell carcinoma; Metastasis; Prognosis; Recurrence; SHIP2

Indexed keywords

REGULATOR PROTEIN; SHIP2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNGECTOMY; LARYNX CARCINOMA; LARYNX SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; PROGNOSIS; RECURRENCE;

EID: 84862961969     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.10.012     Document Type: Article

References (25)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Akoglu E., Dutipek M., Bekis R., et al. Assessment of cervical lymph node metastasis with different imaging methods in patients with head and neck squamous cell carcinoma. J Otolaryngol 2005, 34:384-394.
4. Elsheikh M.N., Rinaldo A., Hamakawa H., et al. Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck 2006, 28:842-849.
5. Arai Y., Shibata T., Matsuoka S., et al. Self-organization of the phosphatidylinositol lipids signaling system for random cell migration. Proc Natl Acad Sci USA 2010, 107:12399-12404.
6. Foukas L.C., Berenjeno I.M., Gray A., et al. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA 2010, 107:11381-11386.
7. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., et al. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010, 11:329-341.
8. Peyrou M., Bourgoin L., Foti M. PTEN in liver diseases and cancer. World J Gastroenterol 2010, 16:4627-4633.
9. Gupta A., Dey C.S. PTEN and SHIP2 regulates PI3K/Akt pathway through focal adhesion kinase. Mol Cell Endocrinol 2009, 309:55-62.
10. Boulton T.G., Nye S.H., Robbins D.J., et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991, 65:663-675.
11. Prasad N.K. SHIP2 phosphoinositol phosphatase positively regulates EGFR-Akt pathway, CXCR4 expression, and cell migration in MDA-MB-231 breast cancer cells. Int J Oncol 2009, 34:97-105.
12. Prasad N.K., Tandon M., Badve S., et al. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis 2008, 29:25-34.
13. Prasad N.K., Tandon M., Handa A., et al. High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumour Biol 2008, 29:330-341.
14. Liu Y., Zhang X., Qiu Y., et al. Clinical significance of EphA2 expression in squamous-cell carcinoma of the head and neck. J Cancer Res Clin Oncol 2011, 137:761-769.
15. Straume O., Akslen L.A. Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer 2005, 93:933-938.
16. Cerezo L., Millan I., Torre A., et al. Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate study of 492 cases. Cancer 1992, 69:1224-1234.
17. Prasad N.K., Decker S.J. SH2-containing 5'-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor. J Biol Chem 2005, 280:13129-13136.
18. Takabayashi T., Xie M.J., Takeuchi S., et al. LL5beta directs the translocation of filamin A and SHIP2 to sites of phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3) accumulation, and PtdIns(3,4,5)P3 localization is mutually modified by co-recruited SHIP2. J Biol Chem 2010, 285:16155-16165.
19. Wang Y., Keogh R.J., Hunter M.G., et al. SHIP2 is recruited to the cell membrane upon macrophage colony-stimulating factor (M-CSF) stimulation and regulates M-CSF-induced signaling. J Immunol 2004, 173:6820-6830.
20. Paternotte N., Zhang J., Vandenbroere I., et al. SHIP2 interaction with the cytoskeletal protein Vinexin. FEBS J 2005, 272:6052-6066.
21. Raaijmakers J.H., Deneubourg L., Rehmann H., et al. The PI3K effector Arap3 interacts with the PI(3,4,5)P3 phosphatase SHIP2 in a SAM domain-dependent manner. Cell Signal 2007, 19:1249-1257.
22. Klippel A., Kavanaugh W.M., Pot D., et al. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol Cell Biol 1997, 17:338-344.
23. Scheid M.P., Huber M., Damen J.E., et al. Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J Biol Chem 2002, 277:9027-9035.
24. Kowalski L.P. Lymph node metastasis as a prognostic factor in laryngeal cancer. Rev Paul Med 1993, 111:42-45.
25. Kowalski L.P., Franco E.L., de Andrade Sobrinho J. Factors influencing regional lymph node metastasis from laryngeal carcinoma. Ann Otol Rhinol Laryngol 1995, 104:442-447.